Four things to know · April 15, 2026
Thymosin Alpha-1
Thymalfasin
Thymosin Alpha-1 (Ta1) is a synthetic version of a peptide your thymus gland naturally produces.
Noticed in days · Full benefit in weeks
Week 1-2
Initial immune system activation typically begins
Week 2-6
Typically enhanced immune function and reduced infection risk
Week 6-12
Full immune-balancing benefits typically reached
Week 12+
Sustained immune support is commonly reported with continued use
Thymosin Alpha-1 (Ta1) is a synthetic version of a peptide your thymus gland naturally produces. The thymus trains your immune cells, and it shrinks as you age. Ta1 is primarily used for immune support: strengthening the body's defenses against infections, supporting immune balance in chronic conditions, and helping the immune system respond more effectively. The evidence base is deep: 30+ clinical trials, over 11,000 patients studied, approval in 35+ countries, and four FDA orphan drug designations. Serious adverse events across all that research have been under 1%.
How it works
Ta1 works by activating and training several types of immune cells. It helps immature T-cells develop into fully functional defenders, boosts the activity of natural killer (NK) cells that patrol for infections and abnormal cells, and improves how your immune system's "scout" cells identify and respond to threats. Think of it as a tune-up for your immune system: it does not just crank up the volume, it helps each part work more effectively.
Key benefits
What the research shows:
- ✓Strengthens overall immune function by activating T-cells and natural killer cells
- ✓Studied extensively across 30+ clinical trials with a strong safety profile
- ✓Approved in 35+ countries for immune support, with four FDA orphan drug designations
- ✓Helps rebalance immune responses rather than simply boosting them
Related goals
Regulatory status
Removed from Category 2 in September 2024 after the original nominator withdrew. The FDA's advisory committee voted against adding it to the 503A bulks list in December 2024. Not currently scheduled for further review. Approved in 30+ countries for immune modulation.
Protocols
| Protocol | Dose | Frequency |
|---|---|---|
| General immune support | 1.6mg | 2x weekly |
| Acute infection support (e.g. sepsis) | 1.6mg | 2x daily x 5 days, then daily |
| Cancer and hepatitis support (adjunctive) | 1.6mg | 2x weekly |
| Ongoing prevention | 1.6mg | 2x weekly |
Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.
What people report
Initial immune system activation typically begins
Typically enhanced immune function and reduced infection risk
Full immune-balancing benefits typically reached
Sustained immune support is commonly reported with continued use
What to know
- ⚠Serious adverse events have been under 1% across 11,000+ patients in clinical trials
- ⚠Do not use if you have had an organ transplant; Ta1 can trigger graft rejection by strengthening immune response
- ⚠Mild injection site reactions (redness, soreness) are the most common side effect, affecting under 10% of users
- ⚠Watch for hypersensitivity reactions with the first dose
- ⚠Avoid during pregnancy or breastfeeding
KEY RESEARCH · 4 PAPERS CITED
The Pep Dispatch
Follow the evidence on Thymosin Alpha-1 as it evolves.
Subscribe to find out what.
Next dispatch · May 2026 · Honest frequency: a few times a month
For the people who want to feel better — not just look up symptoms.